製品名:2-amino-6-methylbenzoic acid

IUPAC Name:2-amino-6-methylbenzoic acid

CAS番号:4389-50-8
分子式:C8H9NO2
純度:95%+
カタログ番号:CM101793
分子量:151.17

包装単位 有効在庫 価格(USD) 数量
CM101793-100g in stock ƥŗNJ
CM101793-500g in stock ǤŹƥ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:4389-50-8
分子式:C8H9NO2
融点:-
SMILESコード:O=C(O)C1=C(C)C=CC=C1N
密度:1.254 g/cm3
カタログ番号:CM101793
分子量:151.17
沸点:
MDL番号:MFCD00007809
保管方法:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Carbonyl Compounds
In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
Tinlorafenib
The Journal of Medicinal Chemistry releases an article titled "Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer". Mutations in the BRAF gene result in MAPK pathway activation that are most commonly found in human melanomas. The BRAF V600E mutation is among the most frequent types. Present BRAF inhibitors have significantly improved treatment outcomes for patients with BRAF V600-mutant cancers. However, their effectiveness is limited by disease progression in the brain as they don’t adequately penetrate the blood-brain barrier (BBB).
Pfizer’s Tinlorafenib (formerly PF 07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188).